Increasing product launches coupled with increasing geographical approval in drug eluting coronary stents is propelling growth of the coronary stents market. For instance, in May 2018, Abbott received the U.S. FDA approval for XIENCE Sierra, the new generation of everolimus-eluting coronary stent. The XIENCE received approval from the Japan’s regulatory body in April 2018, and CE mark from European regulatory bodies in 2017. Furthermore, companies are also evaluating and launching products with novel material, such as with metal like cobalt chromium and fully biodegradable stents.
Request to Sample Report @https://www.coherentmarketinsights.com/insight/request-sample/2031
For instance, in 2017, Medtronic received approval for Onyx drug eluting stents from the U.S. FDA for the treatment of coronary artery disease in adults. In the same year, company also received approval for cobalt chromium coronary stent system, known as Pro-Kinetic energy stents after BIOHELIX-I studies.
Furthermore, in 2017, Cordis launched two products: the Tryton Side Branch Stent and Medinol’s NIRxcell, a cobalt-chromium bare metal stent (BMS) under comprehensive interventional cardiology portfolio at 29th Transcatheter Cardiovascular Therapeutics Symposium. Such product launches in symposiums and conferences are expected to highlight the product and its features to healthcare professionals and distributors, in turn aiding in increasing the customer base of the company.
Mergers and acquisition by key players are further augmenting the coronary stents market growth with major players enhancing their market share and leveraging the strengths of the acquired company. For instance, in February 2018, Stentys confirms its rights to acquire MINVASYS, a France-based cardiovascular disorder solutions specialist, to accelerate its development and to establish as a benchmark in interventional cardiology market.
Request for a sample of this research @https://www.coherentmarketinsights.com/insight/request-customization/2031
Moreover, increasing expansion of regional key players in the other regions is also expected to influence the regional market growth. For instance, in April 2018, Terumo Corporation, Tokyo-based medical device company, received CE mark for Ultimaster TANSEI drug-eluting stent, which was launched in the European market in May 2018. Furthermore, the company also aims to expand in Middle East, Latin America, and Asia in the near future.
Major players operating in the coronary stents market include Boston Scientific Corporation, Abbott, Medtronic plc, B. Braun Melsungen AG, Stentsy SA, Terumo Interventional Systems, Kyoto Medical Planning Co., Ltd., QualiMed, Elixir Medical Corporation, ENDOCOR GmbH, BIOTRONIK SE & Co. KG, Amaranth Medical, Inc. and Arterial Remodeling Technologies SA
Make an inquiry for purchasing this report @https://www.coherentmarketinsights.com/insight/request-discount/2031
Major players operating in the coronary stents market include Boston Scientific Corporation, Abbott, Medtronic plc, B. Braun Melsungen AG, Stentsy SA, Terumo Interventional Systems, Kyoto Medical Planning Co., Ltd., QualiMed, Elixir Medical Corporation, ENDOCOR GmbH, BIOTRONIK SE & Co. KG, Amaranth Medical, Inc. and Arterial Remodeling Technologies SA
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
No comments:
Post a Comment